Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered
intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients
with prostate cancer.